Nedaplatin (cis-diammine-glycolato
platinum: CDGP) is a
platinum compound with a molecular weight of 303.18 that was recently developed in Japan. There have been reports of the
antineoplastic effects of
Nedaplatin on
cancers in the cranio-cervical region, lung, esophagus, urinary bladder, testis, ovary, and uterus. In this study, we performed combined
therapy of CDGP and
fluorouracil (5-FU) for 8 patients with
oral cancers, and evaluated the results to elucidate the clinical effect and adverse side effects. The subjects were 8 patients with
squamous cell carcinoma (5 males and 3 females aged 33-65 years). The primary
carcinoma regions were the tongue in 5 patients, oral floor in 2 patients, and mandibular gingiva in 1 patient. The T-classification was T2 in 6 patients and T4 in 2 patients, and the clinical staging was Stage II in 5 patients, Stage III in 1 patient and Stage IV in 2 patients. We first administered 700 mg/m2
5-FU per day from day 1 to day 5 (total dose 3,500 mg/m2), then 90 mg/m2 CDGP on day 5. The clinical effect was evaluated as a partial response in all cases, showing a 100% success rate. The histopathological findings of resected
tumors were evaluated by Ohboshi and Shimozato's classification. One patient was Grade IIA, 5 patients Grade IIB, and 2 patients Grade III. The adverse side effects were slight myelotoxicity,
gagging,
nausea,
alopecia, and
stomatitis less than Grade II. Although the
oral cancers in this study were extroverted superficial ulcerative
cancers, and the number of patients was low at 8, this combined
therapy is considered useful and worth evaluating in further accumulated cases.